Efficacy and Safety of Insulin Detemir in Combination With Insulin Aspart and Biphasic Insulin Aspart 30 in Type 2 Diabetes

Inclusion Criteria: * Type 2 diabetes * Duration of type 2 diabetes for at least 6 months since diagnosis * Current treatment with one or two oral antidiabetic drugs for at least 3 months or with one or two oral antidiabetic drugs, given for at least 3 months in combination with intermediate or long-acting insulin/insulin analogue once daily * BMI below 40 kg/m2 * HbA1c between 7-12% * Able and willing to perform self-monitoring of capillary blood glucose Exclusion Criteria: * Current antidiabetic treatment with combination of three or more oral antidiabetic drugs * Previous treatment with short-acting human insulin, short-acting insulin analogue or biphasic insulin/insulin analogue within the last 6 months (7 days or less within the last 6 months is allowed) * Known hypoglycaemia unawareness or recurrent major hypoglycaemia, as judged by the Investigator * Known or suspected allergy to trial product or related products * Pregnancy, breast-feeding, the intention of becoming pregnant or judged to be using inadequate contraceptive measures * Receipt of any investigational drug within 4 weeks prior to this trial * Previous participation in this trial